Quick Answer
Aclaris Therapeutics, Inc. reported Net Income of -$64.92 million for fiscal year 2025.
Aclaris Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$64.92M | +50.8% |
| 2024 | -$132.06M | -49.3% |
| 2023 | -$88.48M | -1.8% |
| 2022 | -$86.91M | +4.4% |
| 2021 | -$90.86M | -78.1% |
| 2020 | -$51.02M | +68.4% |
| 2019 | -$161.35M | -21.6% |
| 2018 | -$132.74M | -93.7% |
| 2017 | -$68.52M | -42.5% |
| 2016 | -$48.08M | -133.8% |
| 2015 | -$20.56M | -141.4% |
| 2014 | -$8.52M | -62.7% |
| 2013 | -$5.24M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.61M | -92.6% | +5.3% |
| June 30, 2025 | -$15.43M | -40.4% | -2.3% |
| March 31, 2025 | -$15.09M | +11.0% | -98.9% |
| September 30, 2024 | -$7.59M | +74.1% | +30.9% |
| June 30, 2024 | -$10.99M | +62.8% | +35.2% |
| March 31, 2024 | -$16.94M | +39.8% | +42.1% |
| September 30, 2023 | -$29.26M | -46.7% | +1.0% |
| June 30, 2023 | -$29.57M | -44.0% | -5.0% |
- Aclaris Therapeutics, Inc. showed an increase of +50.8% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, Aclaris Therapeutics, Inc.’s net income has declined by 1139.9% (from -$5.24 million to -$64.92 million).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: